Physician profile
Regina W Smith
NPI 1750360418
$2,400.40
in general payments reported to CMS, 2019-2025
29 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $235 · 2021: $416 · 2022: $619 · 2023: $382 · 2024: $285 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $578.86 | 2019-2025 | Qulipta |
| Novo Nordisk INC | $259.38 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.67 | 2020-2024 | Trulance, Xifaxan |
| Abbott Laboratories | $204.75 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.20 | 2020-2021 | |
| Boston Scientific Corporation | $97.92 | 2019-2020 | |
| Menarini Silicon Biosystems, INC. | $93.44 | 2024-2025 | |
| Lilly USA, LLC | $92.68 | 2022 | |
| Tactile Systems Technology INC | $79.84 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $79.40 | 2019-2025 | Strensiq |
| Histosonics, INC. | $68.96 | 2025 | |
| Grt US Holding, INC. | $57.01 | 2022 | |
| Dexcom, INC. | $56.83 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $48.89 | 2023-2024 | Cologuard Collection Kit |
| Antares Pharma, INC. | $43.96 | 2023-2024 | Xyosted, Tlando, Nocdurna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $40.73 | 2020 | |
| Csl Behring | $34.45 | 2025 | Hizentra |
| Eisai INC. | $33.71 | 2024 | |
| Acella Pharmaceuticals, LLC | $32.54 | 2023 | NP Thyroid 60 |
| Nestle Healthcare Nutrition INC. | $31.18 | 2021-2022 | |
| Vyera Pharmaceuticals, LLC | $23.23 | 2019 | |
| Amgen INC. | $19.50 | 2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $19.10 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.03 | 2022 | |
| Zimmer Biomet Holdings, INC. | $16.26 | 2019 | |
| Allergan, INC. | $15.03 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.88 | 2020 | |
| Nevro Corp. | $13.90 | 2019 | |
| Aimmune Therapeutics, INC. | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.